Lilly to Acquire Calytrix for Up to $1.5 Billion in Antibody Deal

Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion, including an upfront payment and additional payouts contingent on clinical and regulatory milestones. The acquisition gives Lilly access to Calytrix’s preclinical biparatopic antibody program targeting mutant calreticulin, which is linked to some cases of essential thrombocythemia and myelofibrosis. The proposed therapy is designed to target disease-driving cells while sparing healthy tissue, potentially addressing the underlying mutations rather than primarily managing symptoms, as current treatments do. The program has not yet entered clinical testing, so its safety and effectiveness remain unestablished.



